REVB (Revelation Biosciences) Days Payable: 0.00 (As of Mar. 2026)

What is Revelation Biosciences Days Payable?

Revelation Biosciences REVB +3.16% 28 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 707 Biotechnology companies, Revelation Biosciences ranks worse than 141442.57% on this metric.

Revelation Biosciences's average Accounts Payable for the three months ended in Mar. 2026 was $0.70 Mil. Revelation Biosciences's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Revelation Biosciences's Days Payable or its related term are showing as below:

REVB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Revelation Biosciences's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Revelation Biosciences Days Payable Related Terms

Revelation Biosciences Days Payable Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences Days Payable Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Revelation Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

REVB vs ITRMF, ENSC, PPCB: Days Payable Comparison

For the Biotechnology subindustry, Revelation Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Days Payable falls into.

Save Embed

28GF Score

Revelation Biosciences Inc REVB

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Revelation Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Revelation Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (0.784	+	0.578)	/	2 )	/	0	*	365
=	0.681					/	0	*	365
=	N/A

Revelation Biosciences's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (0.578	+	0.828)	/	2 )	/	0	*	365 / 4
=	0.703					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Revelation Biosciences (REVB) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Revelation Biosciences and its competitors. According to the industry distribution chart, Revelation Biosciences ranks #999999 out of 707 companies in the Biotechnology industry.

Is Revelation Biosciences' Days Payable too high?

Revelation Biosciences' current Days Payable is 0.00. Based on the distribution chart, Revelation Biosciences ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Revelation Biosciences' Days Payable compare to ITRMF and ENSC?

According to the Biotechnology industry distribution chart, Revelation Biosciences ranks #999999 out of 707 companies for Days Payable. This places Revelation Biosciences in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Revelation Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revelation Biosciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Revelation Biosciences stock overvalued right now?

Revelation Biosciences (REVB) has a current Days Payable of 0.00. The current Days Payable is 0.00. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies ITRMF ENSC PPCB ACUT LSBCF ALZN SXTP DCOY VIVS AZTR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

28GF Score

Get the complete analysis for REVB

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98

Price

View REVB Analysis

See Days Payable data for all stocks →